NCT02875067

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is to assess the safety \& efficacy of the Combination of Pembrolizumab and Lenalidomide in the management of patients with Relapsed Hodgkin Lymphoma.

Detailed description

There is an emerging clinical data to confirm that Programmed death-1 (PD-1)blockade is safe and viable in lymphoma. The investigators hypothesize that the novel immune platform of pembrolizumab and lenalidomide, will be safe and well tolerated in patients with Relapsed Refractory (RR) Hodgkin Lymphoma (HL) and non-Hodgkin lymphoma (NHL) and that this combination will result in a complete response (CR) rate of 50% in patients with RR HL.

Conditions

• Relapsed Hodgkin Lymphoma
• Relapsed Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	Pembrolizumab
DRUG	Lenalidomide

Timeline

• Start date: 2016-08-29
• Primary completion: 2017-10-02
• Completion: 2017-10-02
• First posted: 2016-08-23
• Last updated: 2020-08-14
• Results posted: 2020-08-14

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study